natgillin/translations-raw huggingface dataset:
The method of Embodiment 5 further comprising a preparation of the compound of formula (4), wherein the method comprises: 
Postupak u skladu s patentnim zahtjevom 4, koji se dodatno sastoji u dobivanju spoja formule (4), naznačen time
For example, as depicted in FIG. 2, rapamycin (II) can be reacted with p-nitrophenyl chloroformate to yield an activated rapamycin (III). 
Na primjer, kako je prikazano na slici 2, rapamicin (II) može reagirati s p-nitrofenil-kloroformijatom da bi dao aktivirani rapamicin (III).
If the adjacent wall elements abut at the position of the upright building element, it is automatically covered. 
Ako se susjedni zidni elementi upiru na mjestu uspravnog građevnog elementa, on je automatski pokriven.
A compound according to claim 18 wherein the bacterial infection is an infection with a gram-positive bacterium. 
Spoj prema zahtjevu 18 naznačen time da je bakterijska infekcija infekcija gram-pozitivnim bakterijama.
A pharmaceutical composition according to claim 2 formulated for oral delivery. 
Farmaceutski sastav prema zahtjevu 10, naznačen time, da se formulira za oralno davanje.
In one aspect, the invention relates to a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5 or a variant of said amino acid sequence. In one embodiment the peptide is 100 or less, 50 or less, 20 or less, or 10 or less amino acids long. 
HR P20190472 T1 PATENTNI ZAHTJEVI Peptid koji sadrži aminokiselinsku sekvencu odabranu iz skupine sastavljene od SEK ID BR: 3, 4 1 5, naznačen time, da je navedeni peptid dužine 100 aminokiselina ili manje, 50 aminokiselina ili manje, 20 aminokiselina ili manje, ili 10 aminokiselina ili manje.
The method of claim 5, wherein said at least one probiotic strain comprises Lactobacillus paracasei 8700:2, DSM 13434, in combination with Lactobacillus plantarum HEAL 9, DSM 15312, and Lactobacillus plantarum HEAL 19, DSM 15313. 
Lactobacillus paracasei 8700:2, DSM13434, za upotrebu prema zahtjevu 1, u kombinaciji sa Lactobacillus plantarum HEAL 9, DSM 15312, i Lactobacillus plantarum HEAL 19, DSM 15313.
In practice, the materials used, so long as they are compatible with the specific use, as well as the dimensions, may be any according to requirements and to the state of the art. 
U praksi, korišteni materijali, dok su god kompatibilni s konkretnom uporabom i dimenzijama, mogu biti sukladni zahtjevima 1 stanju tehnike.
A method for preventing or treating diseases mediated by a neo-angiogenesis process or associated with deregulated angiogenesis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound of Formula Ia or Ib or a pharmaceutically acceptable salt thereof. 
Farmaceutski sastav, naznačen time, da obuhvaća terapeutski učinkovitu količinu spoja prema zahtjevu 1 ili 2, u kombinaciji s farmaceutski prihvatljivim pomoćnim sredstvom.
The catalytic system for the (co)polymerization of conjugated dienes according to claim 6, wherein said compounds or mixtures of compounds (b3) are selected from organic compounds of aluminium and especially boron, such as those represented by the following general formulae: 
Katalitički sustav za (ko)polimerizaciju konjugiranih diena prema patentnom zahtjevu 6, naznačen time što navedeni spojevi ili smjese spojeva (bs) su izabrani od organskih spojeva aluminija 1 naročito bora, kao što su ona predstavljena sljedećim općim formulama:
A suspension according to Claims 1. and 2. characterized in that it contains a C12-18 alcohol-polyglycol ether (EO=5-8) as emulsifier. 
Suspenzija u skladu sa zahtjevima 1 i 2, naznačena time, što sadrži Cy>.13 alkohol -poliglikol eter (EO = 5-8) kao emulgator.
According to the invention, the alkoxylated fat is preferably a polyoxyethylated fatty acid, in particular polyoxyethylated 12-hydroxystearic acid. 
Prema izumu, alkoksilirane masti su povoljno polioksietilirane masne kiseline, posebno polioksietilirana 12hidroksistearinska kiselina.
or a pharmaceutically active acid addition salt thereof. 
1 farmaceutski aktivne soli uz dodatak kiseline.
an associator (252) configured to sequentially associate the sequentially extracted first-type syntax elements to the positions of the transform coefficient block in a scan order among the positions of the transform coefficient block, which depends on the positions of the significant transform coefficients indicated by previously extracted and associated first-type syntax elements. 
Uređaj prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je pridruživač (252) konfiguriran tako, da predodređeni red skeniranja ovisi od pozicija signifikantnih koeficijenata transformacije koji su prikazani putem prethodno izvučenih 1 pridruženih elemenata sintakse prvog tipa.
n represents an integer of 0, 1, 2, 3, 4 or 5; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same. 
C;-Cg-alkil-, C;-Cg-haloalkil-; n predstavlja cijeli broj od 0, 1, 2, 3, 4 1li 5; ili stereoizomer, tautomer, N-oksid, hidrat, solvat, ili njegova sol, ili smjesa istih.
The cell of any one of claims 1-10, wherein the antibody comprises a human constant region and human variable domains. 
Protutijelo ili bispecifično protutijelo sukladno patentnim zahtjevima 1-8, koje sadrži humanu konstantnu regiju i humane varijabilne domene.
A composition comprising the humanized antibody or antibody fragment of any one of claims 1 to 6 in combination with a pharmaceutically acceptable carrier or diluent. 
Kompozicija koja sadrži antitijelo ili fragment antitijela prema bilo kojem od patentnih zahtjeva 1 do 12 ili koje/koji se može dobiti pomoću postupka prema patentnom zahtjevu 18 u kombinaciji sa farmaceutski prihvatljivim nosačem ili razblaživačem.
The method of claim 20, wherein said condition is eosinophilic esophagitis. The method of claim 20, wherein said inflammation comprises inflammation of the glottis, epiglottis, tonsils, or oropharynx. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 16, naznačeno time da navedena upala gastrointestinalnog trakta obuhvaća upalu jednjaka, eozinofilni ezofagitis, ili upalu glotisa, epiglotisa, tonzila ili orofarinksa.
In certain embodiments, the fibrosis is kidney fibrosis and is present in a subject having a disease selected from glomerulosclerosis, tubulointerstitial fibrosis, IgA nephropathy, interstitial fibrosis/tubular atrophy; chronic kidney damage, glomerular disease, glomerulonephritis, diabetes mellitus, idiopathy focal segmental glomerulosclerosis, membranous nephropathy, collapsing glomerulopathy, chronic recurrent kidney infection, and end stage renal disease. In certain embodiments, the kidney fibrosis results from acute or repetitive trauma to the kidney. 
Spoj ili pripravak prema zahtjevu 7, naznačen time da: fibroza bubrega je prisutna kod subjekta koji pati od bolesti izabrane od glomeruloskleroze, tubulointerstitialne fibroze, IgA nefropatije, itersticijske fibroze/tubularne atrofije; kroničnog oštećenja bubrega, glomerularne bolesti, glomerulonefritisa, dijabetes melitusa, idiopatske fokalne segmentne glomeruloskleroze, membranske nefropatije, kolapsne glomerulopatije, kronične recidivirajuće infekcije bubrega, te od zadnjeg stadija bubrežne bolesti; ili fibroza bubrega proizlazi iz akutne ili ponavljajuće traume bubrega.
The pharmaceutical composition according to claim 1, comprising at least two peptides, wherein said peptides comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 10, or SEQ ID NO: 12 to SEQ ID NO: 23; provided that the composition comprises at least one peptide comprising SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 12 or SEQ ID NO: 13 or a variant or salt thereof; and further comprising mannitol and poloxamer 188, wherein the ratio by weight of peptides to mannitol to poloxamer 188 ranges is in the range including and between 1:5:1.5 to 1:8:2.2. 
L IL. Farmaceutski sastav koji uključuje najmanje dva peptida, naznačeno time da se spomenuti peptidi sastoje od slijeda aminokiselina odabranih u skupini koja se sastoji od SEQ ID BR: 1 do SEQ ID BR: 11 pod uvjetom da sastav uključuje najmanje jedan peptid koji se sastoji od SEQ ID NO:1 ili SEQ ID NO:2 ili varijante ili soli spomenutih peptida, te da peptid nije dugolančani polipeptid pridružen humanom tumoru i nadalje, da se sastoji od manitola i poloksamera 188, naznačeno time da je maseni udio peptida u odnosu na manitol i poloksamer 188 u rasponu od 1:5:1,5 do 1:8:2,2.
E is an oxygen atom or an —NR8 group (wherein R8 is a hydrogen atom, or a straight-chain or branched alkyl group having 1 to 5 carbon atoms); 
E je atom kisika ili -NR* skupina pri čemu R* je atom vodika, ili ravnolančana ili razgranata alkil skupina koja sadrži 1 do 5 ugljikovih atoma; ili njegova farmaceutski prihvatljiva sol.
A pharmaceutical combination of Claim 29 wherein the other therapeutic agent is a biguanide and the compound of Claim 1 will be administered in a weight ratio to the biguanide within the range from about 0.001:1 to about 10:1. 
Farmaceutski sastav Zahtjeva 29, naznačen tune, da je drugo terapijsko sredstvo bigvanidin i spoj Zahtjeva 1 će se unositi u masenom omjeru prema bigvanidinu unutar raspona od 0.001:1 do 10:1.
The taps 55 are adapted to engage an edge of a hole of a CD or DVD. 
Lamele 55 su prilagođene tako da zahvate rub otvora CD-a ili DVD-a.
Compound (I) is preferably a crystal. 
(I) gdje R' je skupina prikazana formulom
3-[(3-Chloropropyl)thiol-4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4 H -1,2,4-triazole, as intermediate in the preparation of the compound of formula (I) according to claim 7. 
-[(3-klorpropil)tiol-4-metil-5-(4-metil-1,3-oksazol-5-il)-4H-1,2,4-triazol [image], naznačen time što je međuprodukt u dobivanju spoja formule (I) u skladu s patentnim zahtjevom 7.
Compound of the formula I as claimed in claims 1 to 22 in which 
Spojevi formule I u skladu s patentnim zahtjevima 1 do 22, gdje
melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer, Kaposi's sarcoma, endometrial cancer, head and neck cancer, glioblastoma, malignant ascites, or hematopoietic cancers. 
(D) melanoma, seminoma, teratokarcinoma, osteosarkoma, xenoderoma pigmentosum, keratoktantoma, folikularnog karcinoma štitnjače, Kaposijevog sarkoma, raka endometrija, raka glave i vrata, glioblastoma, malignog ascitesa, ili hematopoetskih rakova.
The umbrella as recited in claim 9, wherein the compressible material is enclosed by an envelope composed of a flexible material whose one end is connected to the valve and whose other end forms an inner tube valve, wherein the gaseous substance can be conveyed into the interior of the inflatable envelope via the inner tube valve. 
Kišobran kao što je navedeno u patentnom zahtjevu 9, naznačen time da je materijal koji se može stlačiti zatvoren unutrašnji cijevni ventil (720), u koji se plinovita tvar može prenijeti u unutrašnjost omotača na napuhavanje putem unutrašnjeg cijevnog ventila.
histidine buffering agent (or histidine buffer system); 
(b) -histidinsko pufersko sredstvo (ili histidinski puferski sastav);
A co-suspension according to claim 8 wherein the pharmaceutically acceptable salt of glycopyrrolate is 3-[(cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide. 
Ko-suspenzija u skladu s patentnim zahtjevom 8, naznačena time što je farmaceutski prihvatljiva sol glikopirolata 3-[(ciklopentilhidroksifenilacetil)oksi]-1,1-dimetilpirolidinijev bromid.
The fastening device according to any of the preceding claims, wherein the inner walls of the sleeve at the first portion of the passage have a constant polygonal cross-section. 
Uređaj za učvršćenje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što unutarnje stijenke tuljka (2) na prvom dijelu (7a) prolaza (7) imaju stalan mnogokutni poprečni presjek.
A compound as claimed in claim 1 or 2, or a pharmaceutically acceptable salt, ester or prodrug thereof wherein A and B are fused to and form part of an unsubstituted or substituted indole. 
Spoj prema zahtjevima 1 ili 6, ili njegova farmaceutski prihvatljiva sol ili njegov farmaceutski prihvatljiv ester, ili farmaceutski sastav prema zahtjevu 2, naznačen(a) time, da RI je CI.
desmodromic tracks (6) controlled in both the vanes sliding directions; 
- < desmodromske staze (6) kontrolirane u oba smjera klizanja krila;
According to the same reasons it is advantageous that the plant growing system is characterized in that a majority or all of said first curvatures of said first guidance panel slots are identical. 
Sustav za uzgajanje biljaka sukladno zahtjevima 2 ili 3, naznačen time što su većina ili su sve navedene sljedeće krivulje navedenih proreza (21) sljedećeg vodećeg panela identične.
The mixing apparatus of claim 1, wherein the mechanism is configured to deform the cartridge at least in part by forcing an upper compression ridge of the cartridge toward a lower compression ridge of the cartridge. 
određivanje barem jedne karakteristike sadržaja uloška (1; 50) koja odgovara odgovoru na čitanje obilježja uloška (1; 50).
The nucleic acid of claim 8, characterized in that it is chosen from the following nucleic acids: 
Izolirana nukleinska kiselina, naznačena time da je odabrana od sljedećih nukleinskih kiselina:
A host cell comprising the nucleic acid or the expression vector according to claim 4, wherein said host cell is not a human embryonic stem cell. 
Stanica domaćin koja se sastoji od nukleinske kiseline u skladu s patentnim zahtjevom 5 ili vektor ekspresije u skladu s patentnim zahtjevom 6, pri čemu navedena stanica domaćin nije ljudska embrionska matična stanica.
a mutation in a gene encoding a component of the HR dependent DNA DSB repair pathway; or 
mutacije gena koji šifrira komponentu puta popravka DSB-a DNK ovisnog o HR-u; ili
Use of the isolated antibody or antigen-binding fragment of any one of claims 1 to 7, or the pharmaceutical composition of claim 8, in the manufacture of a medicament for use in treating a patient who exhibits one or more symptoms or indicia of a disease or disorder caused by PAR-2 activity, wherein the disease or disorder caused by PAR-2 activity is a disease or disorder selected from the group consisting of pain, pruritus, asthma, rheumatoid arthritis, fibrosis, atopic dermatitis, inflammatory bowel disease, ulcerative colitis, pancreatitis, ulcer, Crohn's disease, cancer, and Netherton's disease. 
Primjena izoliranog antitijela 1li antigen vezujućeg fragmenta prema bilo kojem zahtjevu od 1 do 7 ili farmaceutskog pripravka prema zahtjevu 8, u proizvodnji lijeka za primjenu u liječenju bolesnika koji ima jedan ili više simptoma ili indikatora bolesti ili poremećaja izazvanog aktivnošću PAR-2, pri čemu je bolest ili poremećaj izazvan aktivnošću PAR-2 bolest ili poremećaj odabran iz grupe koja se sastoji od boli, pruritusa, astme, reumatoidnog artritisa, fibroze, atopičnog dermatitisa, upalne bolesti crijeva, ulcerativnog kolitisa, pankreatitisa, čira, Chronove bolesti, raka i Nethertonove bolesti. 12.
The admixture of claim 11 or 12, further comprising a buffering agent, preferably potassium acetate. The pharmaceutical composition of any one of claims 1-10 for use in the treatment of heart failure. The pharmaceutical composition of any one of claims 1-10 for use in the treatment of acute decompensated heart failure. 
Spoj patentnog zahtjeva 1 ili patentnog zahtjeva 2 ili farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 3- 7 za primjenu u liječenju srčane insuficijencije. Spoj patentnog zahtjeva 1 ili patentnog zahtjeva 2 ili farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 3- 7 za primjenu u liječenju akutne dekompenzirane srčane insuficijencije.
A non-limiting list of exemplary materials for inclusion in the polymer matrix includes polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethylacrylate copolymers, ethylenevinyl acetate copolymers, silicones, rubber, rubber-like synthetic homo-, co- or block polymers, polyacrylic esters and the copolymers thereof, polyurethanes, polyisobutylene, chlorinated polyethylene, polyvinylchloride, vinyl chloride-vinyl acetate copolymer, polymethacrylate polymer (hydrogel), polyvinylidene chloride, poly(ethylene terephthalate), ethylene-vinyl alcohol copolymer, ethylene-vinyloxyethanol copolymer, silicones including silicone copolymers such as polysiloxane-polymethacrylate copolymers, cellulose polymers (e.g., ethyl cellulose, and cellulose esters), polycarbonates, polytetrafluoroethylene and mixtures thereof. 
Bezgranični popis primjera materijala za uključivanje u polimerni matriks uključuje polietilen, polipropilen, etilen/propilen kopolimere, etilen/etilakrilat kopolimere, etilenvinil acetat kopolimere, silikone, gumu, gumi slične sintetičke homo-, ko- ili blok polimere, poliakrilne estere i njihove kopolimere, poliuretane, poliizobutilen, klorirani polietilen, polivinilklorid, vinil klorid-vinil acetat kopolimer, polimetakrilat polimer (hidrogel), poliviniliden klorid, poli(etilen tereftalat), etilen-vinil alkohol kopolimer, etilen-viniloksietanol kopolimer, silikone uključujući silikon kopolimere kao što su polisiloksan-polimetakrilat kopolimeri, polimere celuloze (npr., etil celuloza, te estere celuloze), polikarbonate, politetrafluoretilen i njihove mješavine.
FIG. 12 illustrates the effect of 42-O-(D-fructosylcarbonyl)rapamycin and rapamycin on survival rates in a rat heart transplant model. 
Slika 12 ilustrira učinak 42-O-(D-fruktozilkarbonil)rapamicina i rapamicina na stopu preživljenja u modelu transplantacije srca štakora.
is selected from the group consisting of and wherein b is an integer from 0 to 4; and wherein c is an integer from 0 to 2; 
[image] je izabran iz skupine koja se sastoji od [image] i [image] gdje je b cijeli broj od 0 do 4; i gdje je c cijeli broj od 0 do 2;
Subsequently, in step d), the aqueous suspension of the ground, and optionally separated, mineral material is concentrated by flash cooling. 
- konačni udio krutih tvari u vodenoj suspenziji dobiven nakon koraka d) je od 80 do 85 % tež..
Within this aim, an object of the present invention is to provide a shoe with breathable and waterproof sole and upper that is structurally simple to obtain. 
Sukladno tome, cilj je predmetnog izuma omogućiti cipelu s prozračnim i vodootpornim potplatom i gornjištem jednostavne konstrukcije i postupka proizvodnje.
Mobile communication system, base station apparatus, and mobile station apparatus 
MOBILNI KOMUNIKACIJSKI SUSTAV, POSTUPAK I UREĐAJ
A compound of Formula 2 wherein R2 is pyridinyl, pyrimidinyl or thiazolyl, each optionally substituted with up to 3 substituents independently selected from the group consisting of halogen and C1-C4 alkyl; 
je piridinil, pirimidinil, oksazolil ili tiazolil, pri čemu je svaki izborno supstituiran sa do 3 supstituenta nezavisno izabrana iz grupe koju čine halogen i C1-C4 alkil.
An improved disposable saliva ejector (1) for use in dentistry provided in a kit comprising: 
PATENTNI ZAHTJEVI 1. - Poboljšana sisaljka (1) za pljuvačku za jednokratnu upotrebu za primjenu u stomatologiji koja se nalazi u kompletu koji sadrži:
Interleukin-2 (IL-2) is a cytokine that promotes the growth and differentiation of T cells in vivo and also enhances the cytotoxicity of CD8+ T cells and natural killer cells. 
Interleukin-2 (IL-2) je citokin koji pospješuje uzgoj i diferencijaciju T stanica in vivo i također proširuje citotoksičnost CD8+ T stanica i prirodnih ubilačkih stanica.
The system according to claim 10, wherein the periodic interval time is based on report interval of the Measurement Report, Time to Trigger (TTT) and mobility of the User Equipment (UE). 
Sustav u skladu s patentnim zahtjevom 10, naznačen time što se periodni interval vremena temelji na intervalu izvješćivanja iz Izvješća O Mjerenju, Vremena Do Okidanja TTT 1 pokretljivosti Korisničke Opreme UE (105).
SUMMARY OF THE INVENTION A first aspect of the invention relates to a sheath device (1) suitable for endoscopic instruments (2), the device comprising: 
Prvi aspekt ovog izuma se odnosi na uređaj za omatanje (1) koji je prikladan za endoskopske instrumente (2), pri čemu ovaj uređaj ima karakteristike patentnog zahtjeva 1, koji patentni zahtjev je ovdje naveden.
For example, the non-circular cross-sectional contour of the launch tube may have a main cross-sectional axis extending in an upright direction to give the ball a forward spin wherein such main axis may be the longer one of the two main axes of an oval or elliptical contour. 
Uređaj za lansiranje kuglice sukladno prethodnom patentnom zahtjevu, naznačen time da je kontura poprečnog presjeka cijevi za lansiranje ovalna ili elipsasta s glavnom osi poprečnog presjeka koja se pruža okomito da bi omogućila zamah okretanju kuglice (4) oko pretežno vodoravne osi.
The container according to any of claims 7 to 10, wherein the inert material coating the internal glass surface of the container is silicon. 
Spremnik prema bilo kojem zahtjevu od 1 do 3, naznačen time da obloga od inertnog materijala na unutarnjoj površini stakla spremnika je silikon.
The resulting suspension was extracted with ethyl acetate (2 × 4 I.). 
Dobivena suspenzija se ekstrahira sa etilacetatom (2x4 1).
ELISA on purified antibodies. 
ELISA na pročišćenim
Table 1: Results of the titer determination 
Broj objave europskog patenta:
at least one member (30) for halting said movable element (20) in the configuration of non-interference, 
- < najmanje jedan element (30) koji drži navedeni pomični element (20) u položaju kada ne djeluje zajedno s navedenom pločom,
MitoTAX can be used for the preparation of drugs for the treatment of neoplastic diseases, especially carcinomas, sarcomas, lymphomas and leukaemias, i.e. for diseases selected from the group: 
Primjena prema zahtjevu 5 za pripremu lijekova za liječenje karcinoma, sarkoma, limfoma i leukemija.
A process according to claim 18, wherein pressure is applied to the peripheral flange at a pressure of from 206.84KPa to 1,241.06KPa (30 psi to 180 psi) for a period of time of from 0.5 seconds to 5 seconds, preferably 758.42KPa (110 psi) for 1 second. 
Postupak prema patentnom zahtjevu 21, pri čemu se pritisak primjenjuje na obod pod tlakom od 206,84 KPa do 1241,06 KPa (30 psi do 180 psi) u periodu od 0,5 sekundi do 5 sekundi, poželjno 758,42 KPa (110 psi) u trajanju 1 sekunda.
the alkylsulfonyl, alkenylsulfonyl, and alkynylsulfonyl optionally are substituted with one or more substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, azido, oxo, aminosulfonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy, alkenyloxy, alkynyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, wherein: 
alkilsulfonil je po izboru supstituiran jednim ili dva supstituenta neovisno odabranima iz skupine koja sadrži karboksi, hidroksi, halo, amino, nitro, okso, aminosulfonil, alkiloksikarbonil, alkilkarboniloksi, alkiloksi, karbociklil, heterociklil, cijano i aminokarbonil; i
A variety of solvents may be used, provided that it has no adverse effect on the reaction or on the reagents involved. 
Tu se može upotrijebiti niz različitih otapala, uz uvjet da to ne utječe štetno na reakciju ili na upotrijebljene reagense.
Each of the support members 4 comprises a generally rectangular frame having an inner upright member 7, an outer upright member 8, and a pair of horizontal connecting members 9, wherein, in use, the lower connecting member 9 bears on the ground and the upper connecting member supports two adjacent segments 6 . 
Sklopiva pozornica za ples na šipki iz zahtjeva 1, pri čemu se svaki nosivi element sastoji od pravokutnog okvira s unutarnjom uspravnom komponentom i vanjskom uspravnom komponentom te od dvije vodoravne spojne komponente, pri čemu se, kad je pozornica u uporabi, donja spojna komponenta naslanja na tlo (podlogu).
Item 39. The use of Item 38, wherein the therapeutic agent is selected from trastuzumab, capecitabine, bevacizumab, paclitaxel and docetaxel. 
Disperzija amorfne krutine, namijenjena upotrebi u skladu s patentnim zahtjevom 4, naznačena time što se terapijsko sredstvo bira između trastuzumaba, kapecitabina, bevacizumaba, paklitaksela i docetaksela.